| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/19/2005 | CN1185227C Novel compounds |
| 01/19/2005 | CN1185215C Substituted glutarimides and use as IL-12 production inhibitors thereof |
| 01/19/2005 | CN1185214C Novel indeno indolone compound, its preparation method and drug composition comprising the same |
| 01/19/2005 | CN1185213C Azetidine derivatives, preparation and pharmaceutical compositions thereof |
| 01/19/2005 | CN1185211C Benzamide derivatives for the treatment of diseases resulted from cytokines |
| 01/19/2005 | CN1185210C Use of naphthalene-carboxylic acid for preparing a medicament used for treating diseases characterized by amyloid aggregation sedimentation |
| 01/19/2005 | CN1184992C Chinese patent medicine for treating paraplegia |
| 01/19/2005 | CN1184987C Medicine for stopping drug addiction and its preparation method |
| 01/19/2005 | CN1184980C Sobering up oral liquid and its preparation process |
| 01/19/2005 | CN1184975C Medicine for treating obsessional neurosis via head acupoint osmosis |
| 01/19/2005 | CN1184969C Use of unsubstituted and substituted N-(pyrrol-1-yl) pyridinamines as anticonvulsant agents |
| 01/19/2005 | CN1184964C Use of carbonylamino derivatives against CNS disorders |
| 01/19/2005 | CN1184962C Sertraline oral condensate |
| 01/18/2005 | US6844457 Antiproliferative agents; anticancer agents; antiinflammatory agents |
| 01/18/2005 | US6844456 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 01/18/2005 | US6844445 Central nervous system disorders; psychological disorders |
| 01/18/2005 | US6844440 Hydrolysis and decarboxylation of 1-alkyl- or aralkyl-4-((2-hydrocarbyloxycarbonyl-5,6-dimethoxyindan-1-one)-2 -yl)methylpiperidine |
| 01/18/2005 | US6844435 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 01/18/2005 | US6844352 1′-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H),4′-piperidine] hydrohalogenides |
| 01/18/2005 | US6844349 Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 01/18/2005 | US6844347 Substituted 4-amino-2aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 01/18/2005 | US6844345 Piperazine derivatives |
| 01/18/2005 | US6844344 Depression, anxiety; tobacco or nicotine withdrawal; such as 1-(benzofuran-4-yl)oxy-3-(4-(6-methoxybenzo(b)thiophen-2-yl)piperidinyl)-2 -propanol oxalate |
| 01/18/2005 | US6844343 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 01/18/2005 | US6844338 Piperidyindoles as serotonin receptor ligands |
| 01/18/2005 | US6844337 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, their preparation and their application in therapeutics |
| 01/18/2005 | US6844336 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity |
| 01/18/2005 | US6844335 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors |
| 01/18/2005 | US6844332 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| 01/18/2005 | US6844331 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| 01/18/2005 | US6844330 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-NOR-vitamin D3 and their uses |
| 01/18/2005 | US6844329 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 01/18/2005 | US6844314 Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| 01/18/2005 | US6844180 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 01/18/2005 | US6844148 Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| 01/18/2005 | US6843989 Administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand |
| 01/16/2005 | CA2465681A1 The use of conjugated linoleic acid or derivative thereof for the treatment of the common cold |
| 01/13/2005 | WO2005003288A2 Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof |
| 01/13/2005 | WO2005003146A1 The c-glycosylisoflavones having alkylaminoalkoxyl substituent, the preparation and the use of the same |
| 01/13/2005 | WO2005003130A1 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 01/13/2005 | WO2005003129A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 01/13/2005 | WO2005003123A1 Novel pyridine derivatives as jnk specific inhibitors |
| 01/13/2005 | WO2005003117A1 Imidazole derivatives iii |
| 01/13/2005 | WO2005003106A1 Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof |
| 01/13/2005 | WO2005003104A2 Crystalline forms of lamotrigine monohydrate and anhydrous lamotrigine and a process for their preparation |
| 01/13/2005 | WO2005003096A1 Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
| 01/13/2005 | WO2005002672A2 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 01/13/2005 | WO2005002624A1 Prolyl oligopeptidase inhibitors ameliorating recovery from brain trauma |
| 01/13/2005 | WO2005002622A1 Pain threshold fall inhibitor |
| 01/13/2005 | WO2005002603A1 Agent for preventing and curing pathological states associated with endorphin deficiency in organism |
| 01/13/2005 | WO2005002587A1 Quetiapine metabolite with antipsychotic activity |
| 01/13/2005 | WO2005002586A1 Metabolite of quetiapine |
| 01/13/2005 | WO2005002583A1 Use of thieno`2,3-d ! pyrimidines for the prophylaxis or treatment of hyperactivity disorder |
| 01/13/2005 | WO2005002580A1 Use of brimonidine for preventing and reducing the severity of stress-associated conditions |
| 01/13/2005 | WO2005002579A1 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 01/13/2005 | WO2005002578A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 01/13/2005 | WO2005002572A2 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | WO2005002568A1 The application of l-n-butylphthlide in preventing and treating dementia |
| 01/13/2005 | WO2005002564A1 Curing and prophylactic agent applied during the use of alcohol and psychoactive substances |
| 01/13/2005 | WO2005002562A1 The combination of a serotonin reuptake inhibitors and agomelatine |
| 01/13/2005 | WO2005002560A1 Use of alverine, alone or in combination with a tricyclic antidepressant or an antidepressant which is a specific inhibitor of serotonin reuptake for treatment of depression |
| 01/13/2005 | WO2005002555A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| 01/13/2005 | WO2005002551A2 Vanilloid receptor (vr) 1 inhibitors for treatment of human immunodeficiency virus (hiv)-mediated pain states |
| 01/13/2005 | WO2004100940B1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
| 01/13/2005 | WO2004091633A8 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
| 01/13/2005 | WO2004082567A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| 01/13/2005 | WO2004064764A3 Substituted alkyl amido piperidines |
| 01/13/2005 | WO2004042077A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) |
| 01/13/2005 | WO2004006958A8 Stable pharmaceutical composition comprising erythropoietin |
| 01/13/2005 | US20050010052 P2X7 receptor (a ligand-gated ion channel) antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases; osteoarthritis |
| 01/13/2005 | US20050010047 Angiogenesis inhibitors; psoriasis; rheumatic disorders; chronic obstructive pulmonary disease |
| 01/13/2005 | US20050009925 Administering atomoxetine or its hydrochloride or a 3-(o-alkylthiophenoxy)-3-phenyl-N-alkylpropylamine for the treatment of cognitive failure, including that due to dementia, delirium and schizophrenia |
| 01/13/2005 | US20050009916 E.g., dextromethorphan hydrobromide, amantadine, memantine, remacemide or riluzole; treating pain resulting from injury, trauma, lesion or other disorders in the spinal cord or brain |
| 01/13/2005 | US20050009905 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 01/13/2005 | US20050009894 Benzimidazole derivatives and their use as KDR kinase protein inhibitors |
| 01/13/2005 | US20050009878 4-(1,2-Dimethyl-1H-imidazol-4-ylethynyl)-2-methyl-pyridine compounds; treating chronic neurological disorders |
| 01/13/2005 | US20050009874 Tetrahydropyridin or piperidino heterocyclic derivatives |
| 01/13/2005 | US20050009872 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| 01/13/2005 | US20050009865 Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
| 01/13/2005 | US20050009861 Inverse agonist has a functional efficacy at the alpha 1 and/or alpha 5 receptor subtypes of less than -5%, and the efficacy measured at the alpha 2 and alpha 3 receptor subtypes is greater than 5%, and is preferably a 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative |
| 01/13/2005 | US20050009856 Administering a compound which inhibits selectively mu opioid receptor activity or activation to treat conditions including Huntington's disease, idiopathic torsion dystonia, tardive dyskinesia or off-dystonia in Parkinson's disease, and dyskinesias arising as a side-effect of a therapeutic agent. |
| 01/13/2005 | US20050009852 human orexin receptor antagonists; analgesics, antidiabetic agents; sleep apnea, insomnia |
| 01/13/2005 | US20050009847 Compounds and methods for increasing neurogenesis |
| 01/13/2005 | US20050009846 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders |
| 01/13/2005 | US20050009841 N-phenylamides and ureas containing both a pyridine, pyrazine, pyrimidine, 1,2,4-triazine, imidazone or oxazine ring and a piperidine or 3,8-diazabicyclo[3.2.1]octane ring, e.g., N-(4-tert-butylphenyl)-3'-chloro-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide |
| 01/13/2005 | US20050009838 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/13/2005 | US20050009822 7-(1-Acetylpentyl)-5-methyl-2-(4-methylbenzyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one; learning enhancement, concentration power, learning power, memory power; enzyme inhibitors of phosphodiesterase isoenzyme |
| 01/13/2005 | US20050009820 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 01/13/2005 | US20050009818 Therapeutic heterocyclic compounds |
| 01/13/2005 | US20050009816 Potassium channel modulators |
| 01/13/2005 | US20050009815 4-Aminoquinoline compounds |
| 01/13/2005 | US20050009814 Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist |
| 01/13/2005 | US20050009813 Use of desoxypeganine for treating clinical depression |
| 01/13/2005 | US20050009808 Azabicyclo compound matrix metalloprotease inibitor and skin preparation |
| 01/13/2005 | US20050009807 Preventing the deposits of amyloid protein, treating neurodegenerative disease, Alzheimer's disease and Down's Syndrome; {[carbamoyl]cycloalkyl}-N-(2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))- or (2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))-carboxamide |
| 01/13/2005 | US20050009796 Use of pregnane-diones or diols as neuropathic analgesic agents |
| 01/13/2005 | US20050009792 (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| 01/13/2005 | US20050009791 Especially lysine, arginine, histidine, omithine and diaminobutyric acid; improved solubility for parenteral administration |
| 01/13/2005 | US20050009779 Preparation for improving the action of receptors |
| 01/13/2005 | US20050009778 Method for treating retinal degeneration with purinergic receptor agonists |